Your browser doesn't support javascript.
loading
Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South Africa.
Centner, C M; Munir, R; Tagliani, E; Rieß, F; Brown, P; Hayes, C; Dolby, T; Zemanay, W; Cirillo, D M; David, A; Schumacher, S G; Denkinger, C M; Ruhwald, M; Leukes, V N; Nicol, M P; Van der Walt, I; Kisten, G; Gumede, M; Mace, A; Brink, A; Stevens, W; Scott, L; Penn-Nicholson, A; Cox, H.
Affiliation
  • Centner CM; Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Munir R; National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
  • Tagliani E; Wits Diagnostic Innovation Hub, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Rieß F; Emerging Bacterial Pathogens Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Brown P; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Hayes C; Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Dolby T; National Health Laboratory Service, Gqeberha, South Africa.
  • Zemanay W; National Health Laboratory Service, Cape Town, South Africa.
  • Cirillo DM; Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • David A; Emerging Bacterial Pathogens Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Schumacher SG; Wits Diagnostic Innovation Hub, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Denkinger CM; Tuberculosis Programme, FIND, Geneva, Switzerland.
  • Ruhwald M; Tuberculosis Programme, FIND, Geneva, Switzerland.
  • Leukes VN; Division of Infectious Disease and Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, and German Center for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.
  • Nicol MP; Tuberculosis Programme, FIND, Geneva, Switzerland.
  • Van der Walt I; Tuberculosis Programme, FIND, Geneva, Switzerland.
  • Kisten G; Marshall Centre for Infectious Diseases Research and Training, School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia.
  • Gumede M; National Health Laboratory Service, Gqeberha, South Africa.
  • Mace A; National Health Laboratory Service, Cape Town, South Africa.
  • Brink A; National Health Laboratory Service, Cape Town, South Africa.
  • Stevens W; Tuberculosis Programme, FIND, Geneva, Switzerland.
  • Scott L; Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Penn-Nicholson A; National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
  • Cox H; Welcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Open Forum Infect Dis ; 11(8): ofae437, 2024 Aug.
Article de En | MEDLINE | ID: mdl-39165581
ABSTRACT

Background:

The World Health Organization-approved Xpert MTB/XDR test detects Mycobacterium tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and injectable drugs directly in specimens. This pragmatic, laboratory-based study assessed the diagnostic accuracy and feasibility of a reflex testing approach, where Xpert MTB/XDR was performed on residual specimens previously processed for Xpert MTB/RIF Ultra.

Methods:

Routine respiratory specimens, processed for Xpert MTB/RIF Ultra, were stored in sample reagent buffer at 2°C-8°C. If rifampicin resistant, the residual specimen was assessed for adequate volume (≥2 mL) and tested with Xpert MTB/XDR, with storage time recorded. A second specimen was used for routine and reference standard testing (culture and sequencing).

Results:

Specimens (99% sputum) from 763 participants submitted to 2 large routine laboratories were included. Xpert MTB/XDR yielded valid resistance detection results in 639 (84%), compared with 507 (66%) for routine testing (difference [95% CI], 18% [13%-22%]). The median turnaround time for results was 23 hours for Xpert MTB/XDR and 15 days for routine testing. While 748 specimens (98%) were ≥2 mL, only 102 (13%) were stored for ≤4 hours. By the reference standard, 284 of 394 (72%) were isoniazid resistant, and 57 of 380 (15%) were fluroquinolone resistant. The sensitivities of Xpert MTB/XDR were 94% (95% CI, 91%-97%) for isoniazid and 91% (81%-97%) for fluoroquinolone resistance detection. The specificities were 98% (94%-100%) and 100% (98%-100%), respectively.

Conclusions:

Xpert MTB/XDR performed favorably compared with the reference, and the reflex testing approach increased results availability over routine testing, while dramatically decreasing turnaround time from weeks to hours. Laboratory workflow precluded testing within the manufacturer-recommended 4-hour storage time, but longer storage did not appear detrimental.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Open Forum Infect Dis Année: 2024 Type de document: Article Pays d'affiliation: République d'Afrique du Sud Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Open Forum Infect Dis Année: 2024 Type de document: Article Pays d'affiliation: République d'Afrique du Sud Pays de publication: États-Unis d'Amérique